×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
PR Newswire
Kazia CEO Dr. John Friend said: "We are pleased to announce we have exclusively licensed the development, manufacture and commercialization of...
1 month ago
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More ...
Yahoo Life UK
Those following along with Kazia Therapeutics Limited ( ASX:KZA ) will no doubt be intrigued by the recent purchase of...
5 days ago
Kazia concludes first stage of Phase I cancer treatment trial
Clinical Trials Arena
Kazia Therapeutics has announced the successful completion of the first stage of the Phase I trial of EVT801 in patients with advanced...
2 weeks ago
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
PR Newswire
The gross proceeds to the Company from the offering were approximately $2 million, before deducting the placement agent's fees and other...
5 months ago
Kazia Therapeutics (NASDAQ:KZIA) Trading 5.2% Higher
Defense World
Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report)'s share price rose 5.2% on Tuesday . The company traded as high as $0.30 and last...
1 week ago
Kazia Provides Overview of Paxalisib Related Presentations From the Society of Neuro-Oncology 2023 Annual Meeting
BioSpace
Published: Nov 21, 2023. SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company,...
5 months ago
Kazia stops paxalisib brain cancer trial early on promising data
BioWorld MedTech
Kazia Therapeutics Ltd. stopped its two-part paxalisib plus radiotherapy phase I trial early based on positive safety and promising clinical...
2 months ago
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
PR Newswire
SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today...
2 months ago
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
Yahoo Movies UK
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
6 days ago
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED ...
PR Newswire
PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the...
2 weeks ago